Re: Medium-Term Outcomes after Whole-Gland High-Intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort
Re: Prostate-Specific Antigen Decline after 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Re: Nadir Testosterone within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent versus Continuous ADT